Objectives Despite advances in our understanding of metabolic syndrome (MetS) and the
treatment of each of its components separately, currently there is no single therapy approved …

Introduction: Cardiovascular disease remains the major contributor to morbidity and mortality
in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such …

Aims Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors, used to treat
type 2 diabetes (T2DM), improve endothelial function. The current study investigated the …

Background Glucose variability (GV) is considered an important factor for cardiovascular
disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial …

ABSTRACT A network meta‐analysis was performed in order to compare the efficacy and
safety of single‐or double‐drug antidiabetic regimens in the treatment of type 2 diabetes …

Так, ранее приоритеты при назначении сахароснижающих препаратов отдавались
применению сенситайзерам к инсулину. А в настоящий момент фокус современного …

Mechanistic intersections between metabolic and cardiovascular disorders are increasingly
appreciated. Novel pharmacotherapies for diabetes and obesity that may simultaneously …

Background: Glucose variability (GV) is considered an important factor for cardiovascular
disease (CVD) in patients with type 2 diabetes mellitus (T2DM). High GV causes endothelial …

ДОСВ²Д ЗАСТОСУВАННЯ В²ЛДАГЛ²ПТИНУ В Р²ЗНИХ КЛ²Н²ЧНИХ СИТУАЦ²ЯХ* Page 1 81
Проблеми ендокринної патології № 4, 2019 ISSN 2518-1432 (Online); ISSN 2227-4782 (Print) …

Diabetes mellitus type 2 is the most important medical problem in many countries within the
world. The features of hypoglycemic drug with high efficiency include the effectivity, safety …